OncLive TV

Julie M. Collins, MD, MPH, discusses the rationale for CDK4/6 inhibitors in endocrine receptor-positive breast cancer.

Raajit K. Rampal, MD, PhD, discusses available tools to estimate prognosis in myelofibrosis.

Peter Martin, MD, discusses the need for head-to-head comparison of BTK inhibitors in mantle cell lymphoma.

Ziad Bakouny, MD, MSc, discusses the rate of disease progression in sarcomatoid carcinoma.

Brian T. Hill, MD, PhD, discusses future research with CAR T-cell therapy in hematologic malignancies.

Seema A. Bhat, MD, discusses the rationale to evaluate acalabrutinib in chronic lymphocytic leukemia.

Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI, discusses the next steps of the phase 3 DASL-HiCAP trial in high-risk prostate cancer.

Ruth O’Regan, MD, discusses the risk of cardiomyopathy associated with trastuzumab in HER2-positive breast cancer.

William W. Tseng, MD, discusses the significance of the Transatlantic Australasian Retroperitoneal Sarcoma Working Group analysis in retroperitoneal sarcoma.

William J. Gradishar, MD, discusses the ​current treatment landscape in metastatic HER2-positive breast cancer.

David H. Vesole, MD, PhD, discusses the importance of developing off-the-shelf CAR T-cell therapy ​products in multiple myeloma.

Matthew S. Davids, MD, MMSc, discusses factors to consider when selecting treatment for patients with chronic lymphocytic leukemia.

Aziz Nazha, MD, discusses the risk of progression to myelofibrosis in patients with polycythemia vera.

Gina Z. D'Amato, MD, discusses the diminishing role of chemotherapy in sarcoma.

Brian T. Hill, MD, PhD, discusses the management of cytokine release syndrome in patients with hematologic malignancies who are treated with CAR T-cell therapy.

Abhinav Deol, MD, discusses the role of CAR T-cell therapy in pediatric patients with acute lymphoblastic leukemia.

Naveen Pemmaraju, MD, discusses the potential role of novel therapies in myeloproliferative neoplasms.

Timothy Yap, MBBS, PhD, FRCP, discusses the rationale for the ongoing phase 1b/2 SEASTAR trial in advanced solid tumors.

Christopher Pleyer, MD, discusses the next steps with ​the combination of ibrutinib and ​short-course fludarabine in previously untreated chronic lymphocytic leukemia.

Robert G. Maki, MD, PhD, FACP, FASCO, discusses the evolving treatment landscape of soft tissue sarcoma.

Philip W. Kantoff, MD, discusses the need to develop new therapies in metastatic castration-resistant prostate cancer.

Christopher Pleyer, MD, discusses the safety and effectiveness of ibrutinib plus short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.

Nancy U. Lin, MD, discusses the challenges faced in the treatment of patients with HER2-positive breast cancer and brain metastases.

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses the exploration of PARP inhibitors in triple-negative breast cancer.

Nicole Concin, MD, discusses the rationale for the ​phase 1/2 LIO-1 trial in advanced gynecologic malignancies.

Alexander N. Shoushtari, discusses the rationale for the ​phase 3 CheckMate-067 trial in advanced melanoma.

Elisavet Paplomata, MD, discusses the clinical impact of tucatinib in HER2-positive breast cancer.

Daniel P. Petrylak, MD, discusses the utility of tissue biopsy versus liquid biopsy in prostate cancer.

Deborah B. Doroshow, MD, PhD, discusses the impact of the coronavirus disease 2019 pandemic on cancer care.

Erlene Seymour, MD, discusses the use of ibrutinib versus chemoimmunotherapy in older patients with untreated chronic lymphocytic leukemia.